首页> 外文期刊>Cancer genomics & proteomics >Topological Network Analysis of Differentially Expressed Genes in Cancer Cells with Acquired Gefitinib Resistance
【24h】

Topological Network Analysis of Differentially Expressed Genes in Cancer Cells with Acquired Gefitinib Resistance

机译:获得性吉非替尼耐药的癌细胞中差异表达基因的拓扑网络分析

获取原文
           

摘要

Background/Aim: Despite great effort to elucidate the process of acquired gefitinib resistance (AGR) in order to develop successful chemotherapy, the precise mechanisms and genetic factors of such resistance have yet to be elucidated. Materials and Methods: We performed a cross-platform meta-analysis of three publically available microarray datasets related to cancer with AGR. For the top 100 differentially expressed genes (DEGs), we clustered functional modules of hub genes in a gene co-expression network and a protein-protein interaction network. We conducted a weighted correlation network analysis of total DEGs in microarray dataset GSE 34228. The identified DEGs were functionally enriched by Gene Ontology (GO) function and KEGG pathway. Results: We identified a total of 1,033 DEGs (510 up-regulated, 523 down-regulated, and 109 novel genes). Among the top 100 up- or down-regulated DEGs, many genes were found in different types of cancers and tumors. Through integrative analysis of two systemic networks, we selected six hub DEGs (Pre-B-cell leukemia homeobox1, Transient receptor potential cation channel subfamily C member 1, AXL receptor tyrosine kinase, S100 calcium binding protein A9, S100 calcium binding protein A8, and Nucleotide-binding oligomerization domain containing 2) associated with calcium homeostasis and signaling, apoptosis, transcriptional regulation, or chemoresistance. We confirmed a correlation of expression of these genes in the microarray dataset. Conclusion: Our study may lead to comprehensive insights into the complex mechanism of AGR and to novel gene expression signatures useful for further clinical studies.
机译:背景/目的:尽管为阐明成功的化学疗法付出了巨大的努力来阐明获得性吉非替尼耐药性(AGR)的过程,但尚不清楚这种耐药性的确切机制和遗传因素。材料和方法:我们对与AGR癌症相关的三个可公开获得的微阵列数据集进行了跨平台的荟萃分析。对于前100个差异表达基因(DEG),我们将集线器基因的功能模块聚集在一个基因共表达网络和一个蛋白质-蛋白质相互作用网络中。我们对微阵列数据集GSE 34228中的总DEG进行了加权相关网络分析。通过基因本体(GO)功能和KEGG途径在功能上丰富了所鉴定的DEG。结果:我们共鉴定了1,033个DEG(510个上调,523个下调和109个新基因)。在上调或下调的前100个DEG中,在不同类型的癌症和肿瘤中发现了许多基因。通过对两个系统网络的综合分析,我们选择了六个集线器DEG(前B细胞白血病同源盒1,瞬态受体电位阳离子通道亚家族C成员1,AXL受体酪氨酸激酶,S100钙结合蛋白A9,S100钙结合蛋白A8和含有2)与钙稳态和信号传导,细胞凋亡,转录调控或化学抗性相关的核苷酸结合寡聚域。我们证实了这些基因在微阵列数据集中表达的相关性。结论:我们的研究可能会导致对AGR复杂机制的全面见解,并有助于新的基因表达特征,以用于进一步的临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号